Skip to content

Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity

Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity: A Prospective Single-Center Non-Inferiority Randomized Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07747779
Acronym
CU BYPASS-DJB
Enrollment
32
Registered
2026-08-05
Start date
2024-08-08
Completion date
2027-07-31
Last updated
2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery, Hormonal Response, Post Bariatric Hypoglycemia

Keywords

Bariatric Surgery, Hormonal Response, Post bariatric hypoglycemia

Brief summary

Obesity is a major global health problem. Bariatric surgery is the most effective treatment, leading to substantial weight loss and improvement in obesity-related comorbidities. The most commonly performed procedures are Laparoscopic Roux-en-Y gastric bypass (LRYGB) and Laparoscopic sleeve gastrectomy (LSG). LRYGB is typically selected for patients with a BMI exceeding 50 kg/m2. Recently, LSG with duodenojejunal bypass (LSG-DJB) has been introduced. To date, no randomized controlled trial has compared LRYGB and LSG-DJB in patients with super morbid obesity, particularly regarding postoperative hormonal responses. This study aims to address this gap. If LSG-DJB results in a lower incidence of post-bariatric hypoglycemia than LRYGB, it would support its clinical benefit. Evaluation of GLP-1, GIP, glucagon, and insulin responses will clarify mechanisms underlying weight loss and postprandial glycemic changes.

Detailed description

Novel bariatric surgical techniques have been developed under the concept of "Sleeve-Plus" procedures, which combine sleeve gastrectomy with intestinal bypass to achieve the metabolic benefits of bypass surgery, including reduced nutrient absorption, while potentially minimizing postoperative complications. Several variations of the Sleeve-Plus procedure have been developed, with laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG-DJB) being one of the most widely adopted techniques developed in Asia. Previous studies have demonstrated that LSG-DJB is comparable to laparoscopic Roux-en-Y gastric bypass (LRYGB) in terms of weight loss, glycemic control, and resolution of obesity-related comorbidities. However, to date, no studies have evaluated changes in gastrointestinal hormone responses following LSG-DJB. This study aims to provide evidence regarding the hormonal changes associated with LSG-DJB compared with the standard laparoscopic Roux-en-Y gastric bypass (LRYGB) procedure. Investigators hypothesize that LSG-DJB may be associated with a lower incidence of post-bariatric hypoglycemia compared with LRYGB, while offering a less technically complex surgical procedure and potentially reducing the risk of other postoperative complications.

Interventions

PROCEDURESleeve gastrectomy with duodenojejunal bypass

Novel bariatric procedure

PROCEDURERoux-en-Y gastric bypass

Standard bariatric procedure

Sponsors

Chulalongkorn University
Lead SponsorOTHER
Ratchadapiseksompotch Research Fund
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients with an indication for bariatric surgery * BMI 50-60 kg/m2 * Patients who are motivated to lose weight but have not achieved successful weight reduction despite optimal medical therapy and exercise under physician supervision

Exclusion criteria

* Patients with diabetes mellitus * Patients with severe comorbid conditions that contraindicate surgery, such as advanced heart disease or chronic kidney failure * Patients with a history of previous bariatric surgery * Patients with gastroesophageal reflux disease refractory to medical therapy, large hiatal hernia, or endoscopic findings of reflux esophagitis grade C or D, or Barrett esophagus * Patients with psychiatric disorders that impair eating behavior control * Patients with a history of pancreatitis, pancreatic disease, or inflammatory bowel disease * Patients who have used steroids or GLP-1 receptor agonists within the past 2 months

Design outcomes

Primary

MeasureTime frameDescription
Hormonal responsePost-operative 6-24 monthsTo compare the hormonal responses following laparoscopic Roux-en-Y gastric bypass (LRYGB) versus laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG-DJB) using a mixed-meal tolerance test (MMTT) in patients with super morbid obesity

Secondary

MeasureTime frameDescription
Post-bariatric hypoglycemiaPost-operative 6-24 monthsTo compare the occurrence of postprandial hypoglycemia following laparoscopic Roux-en-Y gastric bypass (LRYGB) versus laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG-DJB) using a mixed-meal tolerance test (MMTT) in patients with super morbid obesity.

Countries

Thailand

Contacts

CONTACTPrimploy Greeviroj, M.D., M.Sc.
primploy.gre@chulahospital.org+66917142555
PRINCIPAL_INVESTIGATORPatchaya Boonchaya-anant, M.D.

King Chulalongkorn Memorial Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 7, 2026